Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Tumor-Agnostic 1

Conditions

Glioblastoma 2Recurrence 1Neoplasm Metastasis 1Glioma 1

Interventions

Magnetic Resonance Spectroscopy 283Specimen Handling 278pembrolizumab 255Cyclophosphamide 234Radiotherapy 229Nivolumab 183Cisplatin 174Biopsy 165Carboplatin 155Radiosurgery 142fludarabine 130Blood Specimen Collection 130Gemcitabine 120Surveys and Questionnaires 117Paclitaxel 115venetoclax 112Standard of Care 112Dexamethasone 105Bevacizumab 96Radiation 95Rituximab 91Oxaliplatin 89Cytarabine 88Capecitabine 86Drug Therapy 85Ipilimumab 83Doxorubicin 81durvalumab 80fludarabine phosphate 73Fluorouracil 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × AZD1390 × 90 days × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT05678010 2026-05-18

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
54 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05182905 2026-03-09

AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients

St. Joseph's Hospital and Medical Center, Phoenix

Phase EARLY_PHASE1 Active not recruiting
97 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡